Biosimilars Market Report
𝗗𝘂𝗽𝗶𝘅𝗲𝗻𝘁: 𝗧𝗵𝗲 $𝟯𝟬𝗕 𝗠𝗲𝗴𝗮𝗯𝗹𝗼𝗰𝗸𝗯𝘂𝘀𝘁𝗲𝗿. 𝗪𝗶𝗹𝗹 𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗦𝗼𝗮𝗿 𝗼𝗿 𝗦𝗶𝗻𝗸?
New Biosimilar Spotlight: May 29, 2026
𝗧𝗵𝗲 𝗣𝗿𝗶𝘇𝗲:
Dupixent (Dupilumab) from Sanofi/Regeneron delivered ~$18B in 2025 (+26% YoY) and projects $30B peak sales by 2030 making it the most lucrative immunology biosimilar target on the horizon
𝗧𝗵𝗲 𝗣𝗮𝘁𝗲𝗻𝘁 𝗥𝗲𝗮𝗹𝗶𝘁𝘆:
📅 US LoE: 2031 (composition of matter)
🛡️ Patent thicket complexity: Innovators confident of protection beyond 2031
⚠️ Analyst consensus: Min 2-year delay likely; IP clearance route unclear
𝗧𝗵𝗲 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝗼𝗻 𝗙𝗿𝗲𝗻𝘇𝘆:
15+ biosimilar players already targeting Dupixent market, though only 4-5 have reached clinical trials yet. The rest remain in preclinical/technical development; But an insanely competitive marketplace already visible
𝗠𝗮𝗿𝗸𝗲𝘁 𝗛𝗲𝗮𝗱𝘄𝗶𝗻𝗱𝘀 𝗳𝗼𝗿 𝗗𝘂𝗽𝗶𝘅𝗲𝗻𝘁:
🎯 IRA price negotiations kick in post-2030
💊 Oral competitors like KT-621 (FDA Fast Track, Phase II Ongoing) targeting approval by 2030
𝗧𝗵𝗲 𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗣𝗮𝗿𝗮𝗱𝗼𝘅:
💉 Dupilumab, a Medicare Part D product that demands early channel lock-in and PBM contracting for success
✅ Opportunity: Massive addressable market + Experience from Humira/Stelara launches
❌ Risk: Crowded field + Complex IP + Innovator Pricing Negotiations + Oral Competition
𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻:
💰 𝗪𝗶𝘁𝗵 $𝟯𝟬𝗕 𝗮𝘁 𝘀𝘁𝗮𝗸𝗲 𝗯𝘂𝘁 𝗮 𝗱𝗼𝘇𝗲𝗻+ 𝗰𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗼𝗿𝘀, 𝗱𝗶𝗳𝗳𝗶𝗰𝘂𝗹𝘁 𝗜𝗣 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲, 𝗮𝗻𝗱 𝗲𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗮𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲𝘀 – 𝗜𝘀 𝗗𝘂𝗽𝗶𝗹𝘂𝗺𝗮𝗯 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘄𝗼𝗿𝘁𝗵 𝘁𝗵𝗲 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗼𝗿 𝗮 𝘃𝗮𝗹𝘂𝗲 𝘁𝗿𝗮𝗽?
📩 Get in touch for strategic dupilumab analysis
🖼️ Enclosed Image has product details
Market Report by: Ashwinder Singh Chowdhary
Website: https://www.ounsh.com/
Linkedin: https://www.linkedin.com/company/ounsh/
